Ejercicio de rehabilitación y educación de la técnica de aclaramiento de las vías respiratorias en enfermedad pulmonar micobacteriana no tubobacteriana: un estudio de cohorte prospectivo (NTM-Rehab) (NTM-Rehab)
Ejercicio de rehabilitación y educación de la técnica de aclaramiento de las vías respiratorias en enfermedad pulmonar micobacteriana no tubobacteriana: un estudio de cohorte prospectivo
-
The goal of this observational study is to evaluate the effects of pulmonary rehabilitation and airway clearance education in adults with nontuberculous mycobacterial pulmonary disease (NTM-PD). The main questions it aims to answer are:
- Does pulmonary rehabilitation and airway clearance training improve lung function, symptom relief, and quality of life in patients with NTM-PD?
- Does this non-pharmacological intervention contribute to better sputum culture conversion rates?
-
Participants will:
- Undergo pulmonary rehabilitation and airway clearance training over an 8-week period (biweekly sessions).
- Receive evaluations at baseline, during the intervention, and follow-up assessments at 2 months, 6 months, and final study visit.
- Undergo tests including pulmonary function tests (PFT), symptom assessments, bacteriologic evaluations, radiographic imaging (CT/X-ray), and quality of life surveys (EQ-5D-5L, CAT score).
-
This study aims to provide clinical evidence supporting the role of non-pharmacological treatments in the management of NTM-PD, potentially informing future treatment guidelines and improving patient outcomes.
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Hyung-Jun Kim, MD
- Número de teléfono: +82-31-787-7844
- Correo electrónico: dr.hjkim@snu.ac.kr
Ubicaciones de estudio
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Corea del Sur, 13620
- Reclutamiento
- Seoul National University Bundang Hospital
-
Contacto:
- Hyung-Jun Kim, MD
- Número de teléfono: +82-31-787-7844
- Correo electrónico: dr.hjkim@snu.ac.kr
-
Investigador principal:
- Hyung-Jun Kim, MD
-
Sub-Investigador:
- Jaewon Beom, MD
-
-
-
-
Beitou Dist
-
Taipei, Beitou Dist, Taiwán, 112201
- Reclutamiento
- Taipei Veterans General Hospital
-
Contacto:
- Jia-Yih Feng
- Número de teléfono: +886-2-2871-2121
- Correo electrónico: peterofeng@gmail.com
-
Contacto:
- Chih-Jung Chang
- Correo electrónico: rhonda610273@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
This study will enroll adult patients (≥20 years old) diagnosed with nontuberculous mycobacterial pulmonary disease (NTM-PD) based on the 2020 ATS guidelines. Participants will be recruited from outpatient pulmonary clinics at study sites. Eligible participants will undergo pulmonary rehabilitation and airway clearance training as part of a prospective observational study. The study focuses on assessing the effects of non-pharmacological interventions on lung function, symptom relief, and quality of life in patients with NTM-PD.
The cohort will include patients with clinically significant NTM species such as Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium kansasii. Participants will undergo baseline assessment, structured rehabilitation sessions, and follow-up evaluations at 2 months and 6 months. The study aims to provide real-world clinical evidence sup
Descripción
Inclusion Criteria:
- Age 20 years or older at the time of enrollment.
- Diagnosis of nontuberculous mycobacterial pulmonary disease (NTM-PD) according to the 2020 American Thoracic Society (ATS) guidelines.
- Identification of clinically significant NTM species, including:
Mycobacterium avium / Mycobacterium intracellulare / Mycobacterium abscessus / Mycobacterium massiliense / Mycobacterium kansasii /
- Able to undergo pulmonary rehabilitation and airway clearance training as part of the study protocol.
- Willing to provide written informed consent to participate in the study.
Exclusion Criteria:
- Currently pregnant or actively breastfeeding.
- Unable to participate in pulmonary rehabilitation due to severe mobility impairment or neuromuscular disorders.
- History of massive hemoptysis or other medical conditions where airway clearance techniques may be contraindicated.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
NTM-PD Pulmonary Rehabilitation Cohort
This cohort consists of adults diagnosed with nontuberculous mycobacterial pulmonary disease (NTM-PD) who will undergo pulmonary rehabilitation and airway clearance training as part of a prospective observational study. Participants will receive an 8-week biweekly pulmonary rehabilitation program, including oscillating positive expiratory pressure (OPEP) therapy, high-frequency chest wall oscillation (HFCWO), huffing and coughing techniques, breathing exercises, and aerobic/strength training. They will be monitored at baseline, during treatment, and at 2-month and 6-month follow-ups, undergoing pulmonary function tests (PFT), bacteriologic assessments, radiographic imaging (CT/X-ray), symptom evaluations, and quality of life assessments (EQ-5D-5L, CAT score). This study aims to assess the effectiveness of non-pharmacological interventions in improving respiratory function, reducing symptoms, and enhancing quality of life in NTM-PD patients. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Pulmonary Function (FEV1 and FVC) from Baseline to 6 Months
Periodo de tiempo: Baseline, 2 months, 6 months
|
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) will be measured using pulmonary function tests (PFTs) at baseline, after 2 months, and at 6 months to assess improvements in lung function following pulmonary rehabilitation and airway clearance training. |
Baseline, 2 months, 6 months
|
|
Sputum Culture Conversion Rate
Periodo de tiempo: Baseline, 2 months, 6 months
|
The percentage of participants achieving sputum culture conversion, defined as three consecutive negative mycobacterial cultures from respiratory samples collected at least one month apart, will be assessed. |
Baseline, 2 months, 6 months
|
|
6MWT
Periodo de tiempo: Baseline, 2 months, 6 months
|
6 minute walk test distance in meters |
Baseline, 2 months, 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Questionnaire-Bronchiectasis (QOL-B) from Baseline to 6 Months
Periodo de tiempo: Baseline, 2 months, 6 months
|
Quality of life improvements will be assessed using Questionnaire-Bronchiectasis (QOL-B). The questionnaire comprised a total of 37 items, covering domains such as physical functioning (5 items), role functioning (5 items), vitality (3 items), emotional functioning (4 items), social functioning (4 items), health perception (4 items), respiratory symptoms (9 items), and treatment burden (3 items). Each domain score ranged from 0 to 100, with higher scores indicating better quality of life. |
Baseline, 2 months, 6 months
|
|
Change in EuroQoL 5-Dimension 5-Level (EQ-5D-5L) from Baseline to 6 Months
Periodo de tiempo: Baseline, 2 months, 6 months
|
EuroQoL 5-Dimension 5-Level (EQ-5D-5L) includes quality of life assessments including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores can range from 11111 to 55555, with lower scores referring tobetter quality of life. |
Baseline, 2 months, 6 months
|
|
Severity of radiographic findings
Periodo de tiempo: Baseline, 2 months, 6 months
|
High-resolution computed tomography (HRCT) and chest X-rays will be used to evaluate changes in lung structure, including bronchiectasis severity and cavitary lesions. Presence and size of cavities will be measured in chest CT, and artificial intelligenced-based scoring systems will be used to measure radiographic severity in chest X-rays. |
Baseline, 2 months, 6 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Physical Function (Grip Strength, 4-Meter Walk Test, Sit-to-Stand Test) from Baseline to 6 Months
Periodo de tiempo: Baseline, 2 months, 6 months
|
Physical function will be assessed using hand-grip strength measurements, a 4-meter walk test, and a sit-to-stand test to evaluate improvements in muscle strength and mobility. |
Baseline, 2 months, 6 months
|
|
Adverse Events Related to Pulmonary Rehabilitation and Airway Clearance Techniques
Periodo de tiempo: Throughout study period (up to 6 months)
|
The incidence of adverse events such as fatigue, muscle pain, hemoptysis, and respiratory distress related to pulmonary rehabilitation interventions will be monitored and documented. |
Throughout study period (up to 6 months)
|
|
Change in body composition: bioimpeance analysis
Periodo de tiempo: Baseline, 2 months, 6 months
|
Change in body composition will be assesed using the bioimpedance analysis. It provides resistance and reactance measured at different frequency currents, providing estimations of the body fat mass (kg), protein mass (kg), and skeletal muscle mass (kg). Volume of body water (L) and percentage of body fat (%) will be calculated as well. |
Baseline, 2 months, 6 months
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- B-2501-949-303
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
At this time, there is no plan to publicly share individual participant data (IPD) due to patient confidentiality and ethical considerations. However, de-identified, aggregated data may be made available upon reasonable request for collaborative research purposes, subject to appropriate ethical approvals and institutional review board (IRB) regulations. If data sharing becomes feasible, it will follow applicable regulations and data protection guidelines.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .